G&S Capital’s Apellis Pharmaceuticals APLS Stock Holding History

G&S Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-350	Closed	-$9K	–	221
2019 Q2	$9K	Buy	+350	New	+$7.12K	0.01%	185

Other funds holding APLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

G&S Capital's APLS Position: Q3 2019 in Review

G&S Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2019, closing a stake of 350 shares — an estimated $9K sold.

G&S Capital first reported a position in APLS in Q2 2019 and held it in 1 quarter. The position peaked at $9K in Q2 2019. 129 funds tracked by Wall St. Rank hold APLS as of Q3 2019.

G&S Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
G&S Capital sold 350 Apellis Pharmaceuticals shares in Q3 2019, an estimated $9K.
G&S Capital first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 1 quarter.
G&S Capital's Apellis Pharmaceuticals position peaked at $9K in Q2 2019.
129 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2019.

Based on G&S Capital's 13F filing for Q3 2019, filed 17 Oct 2019.